Last reviewed · How we verify
Astaxanthin Oral Capsule
Astaxanthin Oral Capsule, developed by Bangabandhu Sheikh Mujib Medical University in Dhaka, Bangladesh, is currently marketed but lacks a defined primary indication and revenue data. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The absence of detailed clinical trial results and identified competitors poses a significant risk to its market position and strategic planning.
At a glance
| Generic name | Astaxanthin Oral Capsule |
|---|---|
| Also known as | 3,3'-dihydroxy-4,4'-diketo-β-β carotene, |
| Sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dietary Supplement for Myopia Control (NA)
- Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin (NA)
- ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments (PHASE2)
- Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects (NA)
- Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair (NA)
- Efficacy of Investigator Product for the Amelioration of Digital Eye Strain in Children (NA)
- Impact of Astaxanthin on Cognition in Recreationally Active Females (PHASE4)
- Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: